These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 18559580)

  • 1. The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
    Calvert AH; Plummer R
    Clin Cancer Res; 2008 Jun; 14(12):3664-9. PubMed ID: 18559580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
    El-Maraghi RH; Eisenhauer EA
    J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose escalation trial designs based on a molecularly targeted endpoint.
    Hunsberger S; Rubinstein LV; Dancey J; Korn EL
    Stat Med; 2005 Jul; 24(14):2171-81. PubMed ID: 15909289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel designs and end points for phase II clinical trials.
    Adjei AA; Christian M; Ivy P
    Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II clinical trials in oncology: are we hitting the target?
    Ang MK; Tan SB; Lim WT
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):427-38. PubMed ID: 20214523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologically based phase I trials in cancer chemotherapy.
    Newell DR
    Hematol Oncol Clin North Am; 1994 Apr; 8(2):257-75. PubMed ID: 8040140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Methodological approaches of clinical studies with targeted therapies].
    Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
    Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial designs for multiple myeloma.
    Hoering A; Crowley J
    Clin Adv Hematol Oncol; 2007 Apr; 5(4):309-16. PubMed ID: 17607290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing tumor-related signs and symptoms to support cancer drug approval.
    Williams G; Pazdur R; Temple R
    J Biopharm Stat; 2004 Feb; 14(1):5-21. PubMed ID: 15027497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
    Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH
    Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Designs for single- or multiple-agent phase I trials.
    Conaway MR; Dunbar S; Peddada SD
    Biometrics; 2004 Sep; 60(3):661-9. PubMed ID: 15339288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
    Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
    Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'No risk, no fun': challenges for the oncology phase I clinical trial time-performance.
    Verweij J
    Eur J Cancer; 2008 Nov; 44(17):2600-7. PubMed ID: 18951015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New phase I trial methodology.
    Mani S; Ratain MJ
    Semin Oncol; 1997 Apr; 24(2):253-61. PubMed ID: 9129693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
    Hudis CA; Barlow WE; Costantino JP; Gray RJ; Pritchard KI; Chapman JA; Sparano JA; Hunsberger S; Enos RA; Gelber RD; Zujewski JA
    J Clin Oncol; 2007 May; 25(15):2127-32. PubMed ID: 17513820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. End points in cancer clinical trials and the drug approval process.
    Schilsky RL
    Clin Cancer Res; 2002 Apr; 8(4):935-8. PubMed ID: 11948095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Early clinical trial of antineoplastic agents--recent perspectives of pharmacological analysis in phase I study].
    Sasaki Y
    Gan To Kagaku Ryoho; 2001 Mar; 28(3):411-4. PubMed ID: 11265416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimising the design of phase II oncology trials: the importance of randomisation.
    Ratain MJ; Sargent DJ
    Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Cancer Research UK experience of pre-clinical toxicology studies to support early clinical trials with novel cancer therapies.
    Newell DR; Silvester J; McDowell C; Burtles SS;
    Eur J Cancer; 2004 Apr; 40(6):899-906. PubMed ID: 15120045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.